Dostarlimab combination facilitates promising lung cancer survival
The largest head-to-head trial of PD-1 inhibitors for non-squamous non-small…
The largest head-to-head trial of PD-1 inhibitors for non-squamous non-small cell lung cancer suggested dostarlimab with chemo aided survival.